AtriCure, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-92.4% vs price
Base Case (Median)
-89.6% vs price
Bull Case (75th pct.)
-84.4% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.82 | -98.2% | High (40%) |
| PE Comparable | $4.67 | -89.6% | Medium (25%) |
| Graham Number | $6.98 | -84.4% | Medium (40%) |
| EV/EBITDA | $3.40 | -92.4% | Medium (20%) |
| EV/FCF | $24.34 | -45.6% | Medium (20%) |
Based on 5 out of 8 methods, ATRC appears overvalued at the current price of $44.77. The base case fair value of $4.67 implies 89.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.